Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinoma

Table 2 Correlation between the clinicopathological features and 2-year progression-free survival in combined hepatocellular cholangiocarcinoma

Variables	No. of patients	Cumulative 2- year progression-free survival rate	P	HR (95% CI)	P
Age
< 60	28	38.5%	0.941
≧60	24	35.6%	0.941
Gender
Male	37	35.8%	0.097
Female	15	59.3%	0.097
Hepatitis B
Negative	17	39.7%	0.632
Positive	35	44.9%	0.632
Hepatitis C
Negative	36	42.5%	0.747
Positive	16	41.5%	0.747
Liver cirrhosis
No cirrhosis	14	55.1%	0.479
Cirrhosis	38	39.2%	0.479
DM
Negative	38	44.7%	0.575
Positive	14	37.5%	0.575
Gall stone
Negative	47	45.2%	0.178
Positive	5	20.0%	0.178
CEA
≤ 5	45	44.3%	0.311
> 5	7	34.3%	0.311
CA-199
≤ 35	36	43.7%	0.535
> 35	16	19.3%	0.535
AFP
≤ 15	23	26.6%	0.978
> 15	29	43.5%	0.978
Histology grade
Well or Moderate	38	44.9%	0.499
Poorly	14	40.8%	0.499
LVI
Negative	33	50.4%	0.022*
Positive	19	15.0%	0.022*
PNI
Negative	46	44.1%	0.377
Positive	6	33.3%	0.377
Surgical margin
<10 mm	35	35.4%	0.746
≥ 10 mm	17	41.6%	0.746
T stage
TI-II	42	52.3%	< 0.001*	8.004 (2.869-22.336)	< 0.001*
TIII-IV	10	0%	< 0.001*	8.004 (2.869-22.336)	< 0.001*
N stage
Negative	49	43.3%	0.223	4.701 (0.952-23.203)	0.057
Positive	3	33.3%	0.223	4.701 (0.952-23.203)	0.057
AJCC staging
I-II	40	53.2%	< 0.001*
III-IV	12	8.3%	< 0.001*
Midkine expression
Negative	30	60.5%	< 0.001*	4.238 (1.900-9.449)	< 0.001*
Positive	22	8.5%	< 0.001*	4.238 (1.900-9.449)	< 0.001*

ISSN: 1471-2407